Brief: TransCode Therapeutics Issues Open Letter to Shareholders
13/05/2024 13:38
May 13 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS INC: BELIEVE HAVING OUR STOCK
CONTINUE TO
BE LISTED ON NASDAQ CAPITAL MARKET WILL BE VALUABLE IN A NUMBER
OF WAYS
* TRANSCODE THERAPEUTICS INC: WE INTEND TO APPEAL NASDAQ
STAFF
RECOMMENDATION THAT OUR SHARES BE DELISTED
Source text for Eikon: ID:nGNX64rxdX
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors